To evaluate the risk of pleural disorders (PD) associated with 33 protein kinase (PK) inhibitors (PKIs) through a disproportionality analysis and to identify which PKs and pathways are involved in PKI-induced PD.
Introduction
Kinases have emerged as one of the most intensely pursued targets in current pharmacological research (especially for cancer) due to their critical role in both cell signalling and death. The human protein kinase (PK) gene family consists of 518 members, and the strategy behind kinase inhibition was initiated during late the 1980s when inhibitors against epidermal growth factor receptor were described [1, 2] . Since then, many kinase inhibitors with diverse molecular and pharmacological profiles have been approved for several indications. Improperly named targeted therapies, PK inhibitors (PKIs) often have a complex affinity profile while interacting with multiple targets because of critical conserved sequences between PKs genes. Biological consequences of multikinase activities are poorly understood, and investigation of interactions between PKIs and the human kinome could help to elucidate the relationships among selectivity, efficacy and safety of these drugs [3] . Imatinib is one excellent example of this point. Initially, imatinib was first approved in 2001 for chronic myeloid leukaemia as a highly selective inhibitor of Bcr-abl. In the second stage, imatinib was discovered to have significant activity against several other clinically relevant kinases such as kit, which led to the approval for the second indication, gastrointestinal stromal tumours, in 2012 [4, 5] . However, if multikinase activity is unusual for efficacy, it may contribute to adverse drug reaction (ADR) occurrence. Indeed, ADRs can be caused by two separate mechanisms: (i) on-target toxicity, which leads to an ADR being induced by inhibition of the PKI's target of interest; and (ii) off-target toxicity, leading to an ADR caused by inhibition of a secondary or unexpected target (s) of the drug [6] . In this context, pharmacovigilance (PV) data can help to characterize the ADR-associated PKI profiles in clinically relevant situations but also provide elements to allow the identification of pathophysiological pathways that may be involved in these cases. Recently, the study of Patras-deCampaigno et al. highlighted the role of Abelson murine lymphosarcoma (Abl) tyrosine kinases in cardiac failure related to anticancer PKI exposition [7] . Apart from cardiac toxicity, PV PKI reports revealed that pulmonary ADRs such as pleural disorders (PD) could lead to serious effects and/or premature treatment discontinuation with consequent loss of chance for the patient's recovery. Identifying the most at-risk PKIs and understanding the pharmacodynamic mechanisms causing PD would allow ADR developmental mechanisms to be used in order to consider management strategies but would need to anticipate ADR drug candidate profiles. In the present study, we investigated which PKs and pathways are involved in PKI-induced PD. For this purpose we evaluated several approaches: (i) PV data in order to perform a descriptive and disproportionality analysis to identify the PKIs associated with a pharmacovigilance signal; (ii) from a literature review, we determined the PKs for which there is a pharmacological hypothesis linking their inhibition to the occurrence of a PD; and (iii) using PV disproportionality analysis and affinity PK identified profiles, we identified the cellular targets/pathways most likely to be involved in PKI-induced PD.
Methods

Data sources
Pharmacovigilance database. The Uppsala Monitoring Centre receives individual case safety reports (ICSRs) of suspected ADRs sent by national pharmacovigilance centres, which are stored in the World Health Organization's (WHO's) global safety database (VigiBase) [8] . In January 2018, VigiBase contained more than 16 million ICSRs from 127 countries. Each ICSR consists of description of drugs that are suspected to cause ADRs and contains information on patient age, gender, medical history, country, drugs taken, and drug initiation and stop dates. Drugs are coded using the WHO drug dictionary, covering over 150 000 medicines and vaccines.
Data extraction and selection PKI exposure. PKIs were selected according to their ability to inhibit multiple molecular targets. Also, to be included in our analysis, a PKI had to have at least 100 ICSRs reported in VigiBase and at least one PD-related ICSR. Table 1 presents the 33 PKIs meeting the chosen criteria and selected for descriptive and disproportionality analysis. For each PKI, the description of PD was searched in the adverse reaction section of the Summary of Product Characteristics (European Medicines Agency) or the labelling (US Food and Drug Administration). We carried out linear correlation analyses for those with affinity map screened by Davis et al. [9] .
PDs. ADRs are coded according to the Medical Dictionary for Regulatory Activities (MedDRA). There are five levels in the MedDRA hierarchy, arranged from system organ classes with terms very general, to preferred term with specific terms. We identified PD in VigiBase using the following MedDRA preferred term as validated by a pulmonologist: (i) "pleurisy"; (ii) "pleural disorder" (iii) "pleuropericarditis"; and (iv) "pleural effusion».
Affinity data. Data on PKI binding affinities for PKs involved in PD were extracted from the study by Davis et al. [9] . This in vitro study tested the interactions of 72 kinase inhibitors with 442 kinases covering more than 80% of the human catalytic protein kinome. Dissociation constants [expressed as Kd (nmol l -1 )] were converted into products of dissociation constants (pKd = -log 10 (Kd × 10 -9 ; Supporting Information Appendix S1). Although other affinity studies between PKI and PK exist, the study of Davis et al. [9] was selected for the number of tested protein kinases but also to overcome measurement bias related to the use of other methods for the measurement of affinity (such as conversion of half maximal inhibitory concentration to Kd).
Identification of PKs involved in PDs
A literature search (MEDLINE database and WEB OF SCIENCE) was performed with the algorithm presented in the Supporting Information Appendix S2. This search was completed by including references cited in the selected articles. In first step, we selected studies according to the presence of the identification of a PK as a potential mediator for a PD. In the second step, only cellular targets for which a pharmacological mechanism for PD occurrence was discussed or evaluated were selected such as the presence of a link between target inhibition and pulmonary involvement at the cellular level.
Analyses
Descriptive analysis. A descriptive analysis was performed on available data through ICSRs: (i) patient data (sex, age); (ii) characteristics of PD, including seriousness in which seriousness was defined as any untoward medical occurrence that results in congenital anomalies or birth defects; death; life-threatening event; hospital admission and/or prolongation of existing hospital stay; persistent and/or significant disability/incapacity; a case judged as clinically relevant by the physician who reports the case [10] ; (iii) time of onset; (iv) outcome; and (v) PKI characteristics, including posology and indication. The number and proportion of patients were presented for qualitative variables in addition to median and interquartile range or mean and standard deviation for quantitative variables.
Disproportionality analysis. Disproportionality analysis compares the proportion of specific ADRs reported for a single drug with the proportion of the same ADR for all other drugs or for a selected panel of control drugs. Briefly, if the proportion of Y ADRs in patients exposed to drug X is greater than the proportion of Y ADRs in patients not exposed to drug X, this suggests an association between the specific drug and reaction and is a potential signal for safety [11, 12] . In the present study, disproportionality was calculated using the reporting odds ratio (ROR) and its 95% confidence interval (CIs): for each PKI, the ROR is the odds of exposure to the PKI among PD reports divided by the odds of exposure to all the other drugs recorded in the database among all others ADRs reports during the same period. Woolf's method was used to calculate the 95% CI. To detect and quantify a possible masking effect in our study, we undertook sensitivity analysis excluding a subset of reports suspected to induce such an effect. The masking effect is the effect by which a signal of disproportionate reporting for a given drug-event pair might be suppressed by the presence of another product in the same database [13] .
Linear correlation analysis. To determine which suspected cellular targets were involved in PKI-induced PD, we calculated the Pearson correlation coefficients (r) between the affinities of the PKIs (expressed as pKd) for each selected target and their disproportionality (shown as the ROR) for PD. To handle multiple comparisons, the threshold P-value of the test was adapted using a Bonferroni correction. This correction reduced the risk of finding a spurious association with an increased type I error. Scatter plots with trend line, estimate by regression line, for each tested PK were constructed to analyse the characteristics of the linear relationship. Sensitivity analyse, with the exclusion of dasatinib, was carried out to evaluate the weighting of the outlier data points in the linear relationship. All analyses were performed using the statistical software package SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).
Regulatory aspects
This study was registered with the European Network of Pharmacoepidemiology and Pharmacovigilance Centers (ENCePP) coordinated by EMA (EPAS18319). The use of anonymised data from VigiBase abides by the rules for the protection of personal data.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [14] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 [15, 16] .
Results
Pharmacovigilance data
We extracted 235 110 ICSRs pertaining to the 33 selected PKIs (Table 1) . Imatinib, erlotinib and sunitinib were the three drugs most frequently reported in all ICSRs (14.05%, 12.05% and 9.68%, respectively). A total of 5001 ICSRs contained at least one MedDRA preferred term for PD. Dasatinib accounted for almost half of PD ICSRs (47.07%) followed by imatinib (11.92%), erlotinib (7.44%), sunitinib (6.40%) and nilotinib (4.44%). Baseline information contained in the ICSRs is presented in 
Disproportionality analysis
Selection of PKs involved in PD
We identified 11 PKs possibly involved in PDs in the literature review based on the presence of a pharmacological hypothesis. For each PK, the pharmacological hypothesis is assumed in Table 4 .
Relationship between disproportionality for PD and PKI affinity Table 5 . A significant correlation coefficient between pKd and ROR was observed for four proteins kinases: (i) TEC (r = 0.95, P < 0.0001); (ii) Lyn (r = 0.73, P = 0.0004); (iii) Btk (r = 0.72, P = 0.0005); and (iv) Lck (r = 0.62, P = 0.0042). However, after a sensitivity analysis with exclusion of dasatinib, the results showed a significant correlation coefficient only for Lyn (r' = 0.71, P = 0.0008; Table 5 ). The scatter plots with trend lines for Lyn (with or without dasatinib) are presented in Figure 1 and for the other PKs in Supporting Information Appendix S5.
Discussion
Main results In the analysis of the relationship between pKd and ROR, we observed four suspected proteins kinases: (i) TEC (r = 0.95, P < 0.0001); (ii) Lyn (r = 0.73, P = 0.0004); (iii) Btk (r = 0.72, P = 0.0005); and (iv) Lck (r = 0.62, P = 0.0042). Finally, after sensitivity analysis performed [with (r) and without (r') dasatinib] a significant correlation was maintained for the proteins kinase Lyn (r = 0.73, P = 0.0004 and r' = 0.71, P = 0.0008). These results demonstrate some discordance with data in the literature regarding the potential for the PD induction by PKIs. Indeed, data have been found for dasatinib [17] [18] [19] [20] [21] [22] [23] [24] , imatinib [4, [25] [26] [27] [28] , erlotinib [29] , nilotinib [30, 31] , sunitinib [32] and bosutinib [33] , occurrence of PD is mentioned in only seven summary product characteristics among the 33 PKIs of our study that included bosutinib, dasatinib, imatinib, midostaurin, nilotinib, ponatinib and sunitinib. However, PKIs ranking with the highest RORs were those with data listed in literature, expect for ibrutinib, afatinib and alectinib, which were ranked fourth, seventh and eighth, respectively, for which no data were found.
Description of PDs
Dasatinib dose schedule is risk factor for PD [18] . Indeed, posology of 100 mg once daily had a better safety profile with the same efficacy of higher doses; the incidence of pleural effusion was also reduced and, therefore, 100 mg once daily became the recommended initial dosage. Our results showed that for PD reports, the median dose of dasatinib was 100 mg once daily, which is consistent with current recommendations in CML (a majority indication found in our study) but suggesting that the dosage regimen is not yet optimized to reduce the occurrence of PD with dasatinib. This is supported by Rousselot et al. who conducted a study with a therapeutic drug monitoring strategy for dasatinib dose in CML patients during first-line therapy [34] . The incidence of PD decreased from 45% to 11% at five years, and the mean dose of dasatinib after adaptation was 50 mg once daily without efficacy loss.
Numerous missing data were associated with the time of onset and outcome of PD (>60%). On average, PD appears 142 days after the initiation of the PKI, but our results were heterogeneous and depended on the PKI. Comparisons with data from the literature can be made only with dasatinib. In our study, a delayed PD onset with dasatinib was found to be an average of 449 days ( ± 568), which was higher than that found in the literature [median of 5 weeks (1-107); ICSRs with PD were more serious than other ADRs (80.84% vs. 61.23%; P < 0.001). The PD-related deaths (15.26%) occurring with PKIs were indicated in lung cancer (afatinib (7.01%), crizotinib (5.33%), erlotinib (4.84%) and gefitinib (4.41%), except for imatinib (5.20%), which was indicated in CML and sunitinib (5.94%), which was indicated in kidney cancer. This may reflect greater symptom severity with these molecules but also the presence of another aetiology such as the progression of the underlying pathology. Other risk factors for PD such hypertension, history of cardiac diseases or autoimmune diseases, hypercholesterolaemia and/or a history of rash with dasatinib have been identified [19, 25, 34, 35] , but the information gathered in VigiBase did not allow us to analyse these data.
Involvement of protein kinase Lyn in PDs
Our study failed to demonstrate a potential effect from discoidin domain receptor, epidermal growth factor receptors (HER1, HER2, HER3 and HER4) and protein kinase platelet-derived growth factor (PDGFR-β), for which no significant Pearson correlation coefficients were found. Our results refute one of the most widely held assumptions in the literature, which is the involvement of PDGFR-β in PD pathogenesis of PD [18, 25, [35] [36] [37] . Our results show a strong linear correlation for protein kinases of the TEC family tyrosine kinases, including TEC (r = 0.95, P < 0.0001) and BTK (r = 0.72, P = 0.0005). These proteins are recognized as essential antigen receptor signalling mediators in lymphocytes [38] and may be involved in PD pathogenesis via an immune-mediated mechanism [35] . However, the relationship between RORs and pKd is not conclusive for these targets because the slope of the trend lines may have influenced by the outlier dasatinib point (Supporting Information Appendix S5). Sensitivity analysis, with the exclusion of dasatinib, showed a decrease in the correlation coefficients for TEC and BTK (rTEC = 0.50 and rBTK = 0.61, respectively), which Table 4 List of selected molecular targets and associated pharmacological hypothesis
Protein kinase
Physiological process involved Pharmacological hypothesis Reference PDGFR-β Interstitial tissue pressure [46] PDGFR-β is expressed in the pericytes and its inhibition could cause a decrease in the interstitial pressure of the pleural space leading to an increase of the transfer of liquid, thus favouring the appearance of pleural disorder. [18, 25, [35] [36] [37] Lyn Permeability and endothelial stability [47] Inhibition of Lyn could destabilize endothelial barrier leading to an increase endothelial permeability in pulmonary tissue.
[ [35] [36] [37] TEC, BTK, Lck, Lyn, kit
Immune response [48, 49] Cell-mediated immune-mechanism. [23, 24, 35, 42, [50] [51] [52] DDR1 adhesion of epithelial cells to the extracellular matrix [53] DDR1 is expressed on bronchial epithelial cells, transducing signals from the extracellular matrix and plays a role in cell adhesion suggesting it may be a mediator of the pulmonary toxicities.
[35]
HER1-4 Angiogenesis [54] Inhibition of these protein kinases (EGF receptors) could affect the vascular pleural endothelium.
[55]
BTK, Bruton agammaglobulinemia tyrosine kinase; DDR1, discoidin domain receptor family, member 1; EGF, epidermal growth factor; HER, human epidermal growth factor receptor; c-kit, proto-oncogene tyrosine kinase; Lck lymphocyte-specific protein tyrosine kinase; Lyn, v-yes-1 Yamaguchi sarcoma viral related oncogene homologue; PDGFR β, platelet-derived growth factor receptor β; SRC, v-src sarcoma viral oncogene homologue; VEGF, vascular endothelial growth factor; yes, Yamaguchi sarcoma viral related oncogene homologue Table 5 Results of Pearson correlation coefficients with (r) or without dasatinib (r'; with P-values) between reporting odds ratios and product of dissociation constants (pKd; threshold P-value adjusted with Bonferroni's correction = 0.0045) (Table 5 ). These results suggest that BTK and TEC do not seem to be involved in a common pathogenesis PD development with PKIs. Finally, after the sensitivity analysis was performed (with and without dasatinib), a significant correlation was maintained for protein kinase Lyn (r = 0.73, P = 0.0004). The slopes of the trend lines were positive, indicating a positive association between RORs and pKd values (Figure 1) . The scatters had a relatively balanced spread. The relationship between RORs and pKd value seemed to be linear, even though some of the outlier points may have influenced the shape of the line as dasatinib.
The PK Lyn belongs to the Src-family of tyrosine kinases, whose members play critical roles in a variety of cellular signal transduction pathways, regulating such diverse processes as cell division, motility, adhesion, angiogenesis and survival [39] . Specifically, Lyn tyrosine kinase is expressed in B and T lymphocytes and may be involved in the pathogenesis of auto-immune diseases such systemic lupus erythematosus: in these patients, reduced activity of Lyn protein was found [40] . Interestingly, some patients with CML treated with PKIs (imatinib, dasatinib or nilotinib) can develop T cell expansion as an oligoclonal expansion of large granular lymphocytes [41] . These clonal expansions concern CD56+ lymphocytes (natural killer) or CD3+/CD8+ lymphocytes (cytotoxic T lymphocytes), and Lyn inhibition may modulate these immune cells activation [42, 43] .
This clonal large granular lymphocyte expansion have a cytotoxic character on endothelial cells and may be responsible for some ADRs such as fever, colitis, cytomegalovirus reactivation, pulmonary arterial hypertension or PD [43, 44] . Analysis of lymphocytes from pleural fluid showed a similar phenotype (CD3+, CD8+, CD57+) and genotype (identical T-cell clone) as concurrently observed in peripheral blood. Thus, PD induced by PKIs may be part of an antihost response driven by expansion of cytotoxic T and natural killer cells caused by inhibition of Lyn [35, 43] .
Study strengths
RORs were calculated using VigiBase data, which is the most important PV database worldwide. The ROR is a reproducible tool for evaluating PV disproportionality. We performed a thorough literature review to select the most probable PKs involved in drug-induced PD and we assumed the existence of a pharmacological hypothesis concerning the mechanism of PD occurrence. Indeed, a clinical interpretation is always necessary to exclude random or biased signals. The binding properties of a PKI have been screened in in vitro competitive binding assays [9] . For each PKI, Kd values were determined using 11 serial three-fold dilutions and a dimethyl sulfoxide control. This method, used to measure affinity, is accurate and reproducible. We chose to focus our analysis on the tested PKIs using this specific method to avoid bias and errors caused by a change in measurement methods. We gave priority to the most significantly published interaction map for PKs.
Study limitations
PV programs are mostly based on concurrent reporting systems. Consequently, accuracy and the amount of information reported in cases may not be optimal. This could have led to misclassification of PD cases. PV data also suffer from other biases such as underreporting, halo bias, and a lack of information on the exposed population and sales data for the drugs. Indeed, PD may have a tumour aetiology with an over-risk in haematological malignancies and lung and breast cancers. These pathologies are the indications most represented by PKIs in our study and we could not ensure exclusion of another non-drug aetiology. Not being able to return to each notification to ensure that an exhaustive search for aetiologies has been carried out leads to an information bias. Also, in the present study, disproportionality was used as a very early proxy of the relative risk although this relationship is not clear [45] . The screening study of Davis et al. [9] was published in 2011, and only 19 out of the 33 PKIs registered in VigiBase included data to perform the correlation analysis. A more substantial number of points would have made it possible to increase the correlation model robustness. The model used in the analyses to link PV and pharmacodynamics data was based on three hypotheses: (i) PD of a PKI was caused by a single PK. The model was not able to detect coinhibition of multiple PKs or inhibition/activation of non-PK cellular targets (such as proteasomes, G proteincoupled receptors, voltage-gated ion channels or ligand-gated ion channels). Some authors suggest that PKI could cause PD by their ability to inhibit multiple targets as PDGFR-β and SRC family tyrosine kinases [36] . Considering the interactions between PK via an adapted statistical model would have modelled the physiological reality; (ii) we assumed that this mechanism was similar for all the selected PKIs even though there is heterogeneity in this family; and (iii) the relationship between ROR and pKd is simple and straightforward. The relationship between these two parameters may not be linear and, thus, the model would not be able to highlight the molecular targets of interest under these conditions. Accordingly, we observed some heterogeneity within the scatter plots between disproportionality and the affinity of PKIs for Lyn. This difference might have been caused by the uncertainty of measuring two measured variables but also the inadequacy of the model for these drugs. Other cellular mechanisms for PD associated with some PKIs cannot be excluded.
Conclusion
The present study was the first to investigate the disproportionality of PD induced by PKIs in the WHO global safety database. We observed a disproportionality for 29 PKI out of the 33 included in our study. This PV signal remains to be confirmed by appropriate pharmaco-epidemiological studies to inform health professionals and patients about the real PKI risks. Also, we used an approach to combine our PV and pharmacodynamics knowledge in order to identify ADR-related cellular targets. This study highlights the role of Lyn in PD caused by PKIs through an immune-mediated process.
Identification of cellular targets with PV and pharmacodynamics knowledge of approved drugs could allow very early prediction of new drug toxicity, according to the affinity data measured during the preclinical developmental stage.
